Aquinox Pharmaceuticals, Inc. News Releases http://investor.aqxpharma.com/ Aquinox Pharmaceuticals, Inc. News Releases en Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-pharmaceuticals-announces-third-quarter-2018-financial VANCOUVER, British Columbia , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and Wed, 07 Nov 2018 09:15:00 -0500 Aquinox Pharmaceuticals, Inc. News Releases 9036 Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-pharmaceuticals-announces-second-quarter-2018-financial VANCOUVER, British Columbia , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and Wed, 08 Aug 2018 06:15:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8976 Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial Cystitis/Bladder Pain Syndrome http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-announces-topline-results-phase-3-leadership-301 VANCOUVER, British Columbia , June 27, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), today announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome Wed, 27 Jun 2018 06:30:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8941 Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-pharmaceuticals-announces-initiation-proship-phase-2 - Trial Will Enroll Approximately 100 Male Subjects in the US and Canada - VANCOUVER, British Columbia , June 11, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat Mon, 11 Jun 2018 09:05:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8916 Aquinox to Present at 2018 UBS Global Healthcare Conference http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-present-2018-ubs-global-healthcare-conference VANCOUVER, British Columbia , May 16, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (“ Aquinox ”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Wed, 16 May 2018 13:32:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8896 Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-and-astellas-announce-exclusive-licensing-agreement -Aquinox to Receive $25M in Upfront Payment, Potentially Over $100M in Additional Milestone Payments and Royalties- -Astellas to Obtain Development and Commercialization Rights to Rosiptor, Aquinox’s Lead Drug Candidate, in Japan and Certain Other Countries in the Asia-Pacific Region- VANCOUVER, Wed, 09 May 2018 21:00:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8876 Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-pharmaceuticals-announces-first-quarter-2018-financial VANCOUVER, British Columbia , May 08, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate Tue, 08 May 2018 09:05:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8826 Aquinox Pharmaceuticals Announces Year End 2017 Financial Results http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-pharmaceuticals-announces-year-end-2017-financial VANCOUVER, British Columbia , March 12, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a Mon, 12 Mar 2018 16:05:00 -0400 Aquinox Pharmaceuticals, Inc. News Releases 8716 Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-pharmaceuticals-announce-year-end-2017-financial-results Conference call Monday March 12, 2018 at 4:30 PM ET VANCOUVER, British Columbia , March 05, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, Mon, 05 Mar 2018 09:15:00 -0500 Aquinox Pharmaceuticals, Inc. News Releases 8706 Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor http://investor.aqxpharma.com/news-releases/news-release-details/aquinox-provides-enrollment-update-leadership-301-clinical-trial --Enrollment target reached; topline data  on track for Q3 2018 announcement-- NEW YORK , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, Fri, 09 Feb 2018 08:30:00 -0500 Aquinox Pharmaceuticals, Inc. News Releases 8681